Join to View Full Profile
300 Pasteur Dr# StanfordStanford, CA 94305
Phone+1 650-723-4000
Dr. Shu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Endocrinology, Diabetes, and Metabolism, 2006 - 2009
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2003 - 2006
Harvard Medical SchoolClass of 2003
Certifications & Licensure
CA State Medical License 2012 - 2025
TX State Medical License 2010 - 2024
NY State Medical License 2006 - 2011
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency Start of enrollment: 2017 Nov 13
Publications & Presentations
PubMed
- 5 citationsEfficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.Bart L Clarke, Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes
The Journal of Clinical Endocrinology and Metabolism. 2025-03-17 - Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results.Aristides K Maniatis, Paul S Thornton, Ulhas M Nadgir, Elpis Vlachopapadopoulou, Oleg Malievskiy
Hormone Research in Paediatrics. 2025-03-06 - 9 citationsPalopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.Lars Rejnmark, Elvira O Gosmanova, Aliya A Khan, Noriko Makita, Yasuo Imanishi
Advances in Therapy. 2024-06-01
Press Mentions
New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of LifeJuly 14th, 2025- Ascendis Pharma A/S Announces Presentations for Its Endocrinology Rare Disease Clinical Programs at Upcoming Medical ConferencesOctober 21st, 2020
- Ascendis Pharma A/S Announces Presentations for Its Endocrinology Rare Disease Clinical Programs at Upcoming Medical ConferencesOctober 21st, 2020
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
